These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34847142)

  • 1. Avidity observed between a bivalent inhibitor and an enzyme monomer with a single active site.
    Lacham-Hartman S; Shmidov Y; Radisky ES; Bitton R; Lukatsky DB; Papo N
    PLoS One; 2021; 16(11):e0249616. PubMed ID: 34847142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin.
    Salameh MA; Soares AS; Navaneetham D; Sinha D; Walsh PN; Radisky ES
    J Biol Chem; 2010 Nov; 285(47):36884-96. PubMed ID: 20861008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.
    Pendlebury D; Wang R; Henin RD; Hockla A; Soares AS; Madden BJ; Kazanov MD; Radisky ES
    J Biol Chem; 2014 Nov; 289(47):32783-97. PubMed ID: 25301953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin.
    Cohen I; Coban M; Shahar A; Sankaran B; Hockla A; Lacham S; Caulfield TR; Radisky ES; Papo N
    J Biol Chem; 2019 Mar; 294(13):5105-5120. PubMed ID: 30700553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.
    Alloy AP; Kayode O; Wang R; Hockla A; Soares AS; Radisky ES
    J Biol Chem; 2015 Aug; 290(35):21523-35. PubMed ID: 26175157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.
    Cohen I; Kayode O; Hockla A; Sankaran B; Radisky DC; Radisky ES; Papo N
    Biochem J; 2016 May; 473(10):1329-41. PubMed ID: 26957636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands.
    Vauquelin G; Bricca G; Van Liefde I
    Fundam Clin Pharmacol; 2014 Oct; 28(5):530-43. PubMed ID: 24118041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of Alzheimer's amyloid beta-protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI): engineering of inhibitors with altered specificities.
    Scheidig AJ; Hynes TR; Pelletier LA; Wells JA; Kossiakoff AA
    Protein Sci; 1997 Sep; 6(9):1806-24. PubMed ID: 9300481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The amyloid precursor protein/protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin.
    Salameh MA; Robinson JL; Navaneetham D; Sinha D; Madden BJ; Walsh PN; Radisky ES
    J Biol Chem; 2010 Jan; 285(3):1939-49. PubMed ID: 19920152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.
    Vauquelin G; Charlton SJ
    Br J Pharmacol; 2013 Apr; 168(8):1771-85. PubMed ID: 23330947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and characterization of bivalent peptide ligands targeted to G-protein-coupled receptors.
    Carrithers MD; Lerner MR
    Chem Biol; 1996 Jul; 3(7):537-42. PubMed ID: 8807885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a True Bivalent Ligand with Picomolar Binding Affinity for a G Protein-Coupled Receptor Homodimer.
    Pulido D; Casadó-Anguera V; Pérez-Benito L; Moreno E; Cordomí A; López L; Cortés A; Ferré S; Pardo L; Casadó V; Royo M
    J Med Chem; 2018 Oct; 61(20):9335-9346. PubMed ID: 30257092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
    J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of rigid or flexible linkage between two ligands on the effective affinity and avidity for reversible interactions with bivalent receptors.
    Bobrovnik SA
    J Mol Recognit; 2007; 20(4):253-62. PubMed ID: 17847051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative modeling assesses the contribution of bond strengthening, rebinding and force sharing to the avidity of biomolecule interactions.
    Lo Schiavo V; Robert P; Limozin L; Bongrand P
    PLoS One; 2012; 7(9):e44070. PubMed ID: 23024747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A general model for predicting the binding affinity of reversibly and irreversibly dimerized ligands.
    Foreman KW
    PLoS One; 2017; 12(11):e0188134. PubMed ID: 29166663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using covalent dimers of human carbonic anhydrase II to model bivalency in immunoglobulins.
    Mack ET; Snyder PW; Perez-Castillejos R; Whitesides GM
    J Am Chem Soc; 2011 Aug; 133(30):11701-15. PubMed ID: 21671600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate and inhibitor-induced dimerization and cooperativity in caspase-1 but not caspase-3.
    Datta D; McClendon CL; Jacobson MP; Wells JA
    J Biol Chem; 2013 Apr; 288(14):9971-9981. PubMed ID: 23386603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases.
    Cohen I; Naftaly S; Ben-Zeev E; Hockla A; Radisky ES; Papo N
    Biochem J; 2018 Apr; 475(7):1335-1352. PubMed ID: 29535275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin.
    Salameh MA; Soares AS; Hockla A; Radisky ES
    J Biol Chem; 2008 Feb; 283(7):4115-23. PubMed ID: 18077447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.